Olfr1053 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the Olfr1053 protein, which is an olfactory receptor belonging to the large family of G-protein-coupled receptors (GPCRs). Olfactory receptors like Olfr1053 are primarily responsible for detecting odorant molecules in the environment and initiating the signal transduction pathways that lead to the perception of smell. These receptors are embedded in the membranes of olfactory sensory neurons and are highly selective, each responding to a specific set of odorant molecules. Inhibitors of Olfr1053 are typically small molecules that bind to the receptor's binding pocket or other critical regions, thereby blocking the interaction between the receptor and its natural odorant ligands. This inhibition prevents the receptor from activating its associated G-protein and halts the subsequent signaling cascade, effectively modulating the olfactory response.
The development of Olfr1053 inhibitors involves detailed structural and functional analysis of the receptor. High-throughput screening techniques are often employed to identify potential inhibitory compounds that can interact with the receptor's binding site. Once identified, these lead compounds are optimized through structure-activity relationship (SAR) studies, where chemical modifications are made to enhance their binding affinity, specificity, and stability. The chemical structures of Olfr1053 inhibitors are diverse, typically incorporating functional groups that enable strong interactions with the receptor, such as hydrogen bonding, hydrophobic contacts, and van der Waals forces. Structural biology methods, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are used to visualize these interactions at the molecular level, providing insights that guide the design and refinement of these inhibitors. Achieving high selectivity is a key objective in the development of Olfr1053 inhibitors, ensuring that these compounds specifically target Olfr1053 without affecting other olfactory receptors or GPCRs with similar structures. This selectivity is crucial for understanding the precise role of Olfr1053 in olfactory perception and for investigating the broader mechanisms underlying the sense of smell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Inhibits DNA methyltransferases, potentially affecting gene expression and proteins involved in epigenetic regulation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Inhibits MEK1/2, potentially affecting proteins in the MAPK/ERK pathway. | ||||||
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $91.00 $255.00 | 32 | |
Alkylates/methylates DNA, potentially affecting DNA repair proteins and gene expression. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
Inhibits PI3K, potentially altering proteins involved in the AKT/mTOR signaling pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple tyrosine kinases, potentially affecting proteins involved in cell signaling and growth. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Inhibits JAK1/2, potentially affecting proteins in cytokine signaling pathways. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially influencing apoptosis-related proteins. | ||||||